Login to Your Account

Genmab Shares Slide as It Shelves Zalutumumab

By Cormac Sheridan

Monday, June 27, 2011
Shares in Genmab A/S dropped 11 percent Friday on news that the company had failed to secure a deal for its epidermal growth factor receptor (EGFR) inhibitor zalutumumab and has opted to shelve the program.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription